PIVKA-II IRMA「第一」^<【○!R】>の基礎および臨床的検討 Fundamental and Clinical Evaluation of a PIVKA-II Kit, "PIVKA-II IRMA 'Daiichi, ^<【○!R】>"
<I>We evaluated the characteristics and clinical efficacy of the"PIVKA-II IRMA'Daiichi, <SUP>®</SUP>"kit for estimating the serum PIVKA-II levels in hepatocellular carcinoma patients. Intraassay and interassay variances were within 10%. Recovery and dilution tests also gave satisfactory results. There was no significant effect of reaction time on PIVKA-II levels. However, PIVKA-II levels were significantly lower in heparinized plasma than those in serum and EDTA plasma. The cut-off level was determined as 40</I>mAU/mL, <I>mean +3SD of PIVKA-11 level in 84 normal control subjects. The sensitivity and specificity of"PIVKA-IIIRMA lsquo;Daiichi, <SUP>®</SUP>"kit for hepatocellular carcinoma patients was 81; 6% and 82.4%, respectively. A significant correlation was observed between PIVKA-II levels measured by"PIVKA-II IRMA'Daiichi, <SUP>®</SUP>"kit and "EitestR Mono P II"EIA kit (r=979) . In conclusion, "PIV-KA-II IRMA'Daiichi, <SUP>®</SUP> kit is considered to be accurate and useful for measuring PIVKA-II levels in hepatocellular carcinoma patients.</I>
Radioisotopes 48(3), 188-194, 1999-03-15